Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
EW 
Edwards Lifesciences Corp (EW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: EW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -27.78% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 42.10B USD | Price to earnings Ratio 30.71 | 1Y Target Price 80.14 |
Price to earnings Ratio 30.71 | 1Y Target Price 80.14 | ||
Volume (30-day avg) 4488143 | Beta 1.12 | 52 Weeks Range 58.93 - 95.25 | Updated Date 04/1/2025 |
52 Weeks Range 58.93 - 95.25 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.34 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 76.75% | Operating Margin (TTM) 25.54% |
Management Effectiveness
Return on Assets (TTM) 8.26% | Return on Equity (TTM) 16.64% |
Valuation
Trailing PE 30.71 | Forward PE 29.24 | Enterprise Value 39040974848 | Price to Sales(TTM) 7.8 |
Enterprise Value 39040974848 | Price to Sales(TTM) 7.8 | ||
Enterprise Value to Revenue 7.03 | Enterprise Value to EBITDA 22.2 | Shares Outstanding 585755008 | Shares Floating 581844630 |
Shares Outstanding 585755008 | Shares Floating 581844630 | ||
Percent Insiders 0.9 | Percent Institutions 88.79 |
Analyst Ratings
Rating 3.7 | Target Price 79.57 | Buy 5 | Strong Buy 9 |
Buy 5 | Strong Buy 9 | ||
Hold 19 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Edwards Lifesciences Corp
Company Overview
History and Background
Edwards Lifesciences was founded in 1958 by Miles "Lowell" Edwards. Originally part of Baxter International, it became an independent, publicly traded company in 2000. Edwards has been a pioneer in heart valve replacement technology and hemodynamic monitoring.
Core Business Areas
- Transcatheter Aortic Valve Replacement (TAVR): This segment focuses on minimally invasive heart valve replacement technologies, primarily TAVR, for patients with severe aortic stenosis who are at high risk or inoperable for traditional open-heart surgery.
- Surgical Structural Heart: This segment includes surgical heart valve repair and replacement technologies, as well as related surgical products used in open-heart surgery.
- Critical Care: This segment offers hemodynamic monitoring systems, catheters, and related technologies used in intensive care units and operating rooms to monitor patients' cardiovascular function and guide clinical decisions.
Leadership and Structure
The current CEO is Bernard Zovighian. Edwards Lifesciences has a traditional corporate structure with a board of directors and executive leadership overseeing the various business segments and corporate functions.
Top Products and Market Share
Key Offerings
- SAPIEN Transcatheter Heart Valve: Edwards SAPIEN valves are the leading TAVR technology. They are used in minimally invasive procedures to replace damaged aortic valves. Edwards maintains a significant market share in the TAVR market, estimated to be around 50%. Competitors include Medtronic (MDT) and Abbott (ABT).
- INSPIRIS RESILIA Aortic Valve: A surgical aortic valve made with RESILIA tissue designed for durability. Competitors include Medtronic (MDT) and Abbott (ABT).
- HemoSphere Advanced Monitoring Platform: A hemodynamic monitoring system used in critical care settings to assess cardiovascular function. Competitors include ICU Medical (ICUI) and Baxter (BAX).
Market Dynamics
Industry Overview
The medical device industry is experiencing growth due to an aging population, increasing prevalence of cardiovascular diseases, and technological advancements in minimally invasive procedures. The competitive landscape is characterized by innovation, regulatory scrutiny, and pricing pressures.
Positioning
Edwards Lifesciences is a leader in heart valve technologies and hemodynamic monitoring. Its competitive advantages include a strong brand reputation, a large installed base of products, and a robust research and development pipeline.
Total Addressable Market (TAM)
The global market for heart valve devices and hemodynamic monitoring is estimated to be $10+ billion annually, and is expected to grow. Edwards Lifesciences is well-positioned to capture a significant portion of this market, leveraging its established market presence and innovative product portfolio.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Leading market position in TAVR
- Robust R&D pipeline
- Extensive global sales and distribution network
- Proprietary technologies and intellectual property
Weaknesses
- High product prices
- Dependence on TAVR market
- Exposure to regulatory risks
- Patent expiry on key products
- Reliance on reimbursement approvals
Opportunities
- Expanding TAVR indications to lower-risk patients
- Developing new heart valve technologies
- Entering emerging markets
- Acquiring complementary businesses
- Expanding hemodynamic monitoring solutions
Threats
- Increased competition from Medtronic and Abbott
- Pricing pressure from healthcare providers
- Changes in regulatory requirements
- Economic downturns
- Product recalls or safety concerns
Competitors and Market Share
Key Competitors
- MDT
- ABT
- BSX
Competitive Landscape
Edwards Lifesciences has a strong competitive position due to its focus on innovation and high quality products. However, the company faces competition from larger medical device companies with broader product portfolios. Edwards Lifesciences is able to differentiate itself through its specialization in heart valve technologies and hemodynamic monitoring.
Major Acquisitions
Valcare Medical
- Year: 2019
- Acquisition Price (USD millions): 50
- Strategic Rationale: Expanded Edwardsu2019 portfolio of transcatheter mitral and tricuspid therapies.
Growth Trajectory and Initiatives
Historical Growth: Edwards Lifesciences has experienced consistent growth in revenue and earnings over the past years, driven by the increasing adoption of TAVR and hemodynamic monitoring technologies.
Future Projections: Analysts expect Edwards Lifesciences to continue to grow at a solid pace over the next few years, driven by the expansion of TAVR indications and the introduction of new products. Revenue growth is projected to be in the mid to high single digits.
Recent Initiatives: Edwards Lifesciences is investing in research and development to develop new heart valve technologies and expand its hemodynamic monitoring solutions. The company is also expanding its presence in emerging markets and pursuing strategic acquisitions.
Summary
Edwards Lifesciences is a leading medical device company with a strong position in the growing market for heart valve technologies. The company's growth is driven by its innovative products, strong brand reputation, and expanding global presence. However, Edwards Lifesciences faces competition from larger medical device companies and pricing pressure from healthcare providers. Overall, Edwards Lifesciences is a well-positioned company with a solid growth trajectory, however it must keep ahead of new medical device technologies to keep market share.
Similar Companies
- MDT
- ABT
- BSX
- BDX
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Edwards Lifesciences Corp
Exchange NYSE | Headquaters Irvine, CA, United States | ||
IPO Launch date 2000-03-27 | CEO & Director Mr. Bernard J. Zovighian | ||
Sector Healthcare | Industry Medical Devices | Full time employees 15800 | Website https://www.edwards.com |
Full time employees 15800 | Website https://www.edwards.com | ||
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands. It also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.